1-3 of 3
Giovanna Loglisci
Close
Sort by
Journal Articles

Five Years after Frontline Tyrosine-Kinase Inhibitor (TKI) Treatment Initiation for Chronic Myeloid Leukemia: What Does It Happen in a Real-Life Setting?

Daniela De Benedittis, MD, Massimo Breccia, MD, Ida Carmosino, Elena Mariggiò, MD, Matteo Molica, MD, Sara Mohamed, MD, Fulvio Massaro, MD, Maria Lucia De Luca, MD, Emilia Scalzulli, MD, Chiara Lisi, MD, Mauro Passucci, MD, Gioia Colafigli, MD, Maria Giovanna Loglisci, MD, Daniela Diverio, Marco Mancini, Robin Foà, MD, Roberto Latagliata
Journal: Blood
Blood (2018) 132 (Supplement 1): 1746.
https://doi.org/10.1182/blood-2018-99-117272
Published: 2018
Journal Articles

Event-Free Survival According to Age in Patients with Chronic Myeloid Leukemia Receiving Imatinib Frontline: The Younger, the Later, the Worse?

Roberto Latagliata, Massimo Breccia, MD, Ida Carmosino, Federico Vozella, Federico De Angelis, Chiara Montagna, Maria Lucia De Luca, Gioia Colafigli, Luisa Quattrocchi, Giovanna Loglisci, Angela Romano, Paola Volpicelli, Daniela Diverio, PhD, Marco Mancini, Giuliana Alimena
Journal: Blood
Blood (2015) 126 (23): 4038.
https://doi.org/10.1182/blood.V126.23.4038.4038
Published: 2015
Journal Articles

FLT3-ITD Internal Tandem Duplication Confers Poor Prognosis In Patients With Acute Promyelocytic Leukemia Treated With The AIDA Protocols. Long-Term Follow-Up Analysis

Massimo Breccia, Giuseppina Loglisci, MD, Maria Giovanna Loglisci, Phd, Roberto Ricci, Daniela Diverio, PhD, Roberto Latagliata, MD, Robin Foà, Francesco Lo Coco, MD
Journal: Blood
Blood (2013) 122 (21): 1336.
https://doi.org/10.1182/blood.V122.21.1336.1336
Published: 2013